207 related articles for article (PubMed ID: 16175142)
1. The role of therapeutic monitoring of everolimus in solid organ transplantation.
Mabasa VH; Ensom MH
Ther Drug Monit; 2005 Oct; 27(5):666-76. PubMed ID: 16175142
[TBL] [Abstract][Full Text] [Related]
2. Review of the proliferation inhibitor everolimus.
Nashan B
Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
[TBL] [Abstract][Full Text] [Related]
3. [Level of evidence for therapeutic drug monitoring of everolimus].
Goirand F; Royer B; Hulin A; Saint-Marcoux F;
Therapie; 2011; 66(1):57-61. PubMed ID: 21466779
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
[TBL] [Abstract][Full Text] [Related]
5. Analytical performance of QMS everolimus assay on ortho Vitros 5,1 FS fusion analyzer: measuring everolimus trough levels for solid organ transplant recipients.
Shu I; Wright AM; Chandler WL; Bernard DW; Wang P
Ther Drug Monit; 2014 Apr; 36(2):264-8. PubMed ID: 24232125
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.
Starling RC; Hare JM; Hauptman P; McCurry KR; Mayer HW; Kovarik JM; Schmidli H
Am J Transplant; 2004 Dec; 4(12):2126-31. PubMed ID: 15575918
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with everolimus (Certican) in young renal transplant recipients.
Eris J
Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.
Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H
Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of everolimus.
Kirchner GI; Meier-Wiedenbach I; Manns MP
Clin Pharmacokinet; 2004; 43(2):83-95. PubMed ID: 14748618
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
Kovarik JM; Hsu CH; McMahon L; Berthier S; Rordorf C
Clin Pharmacol Ther; 2001 Sep; 70(3):247-54. PubMed ID: 11557912
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
15. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.
Kovarik JM; Tedesco H; Pascual J; Civati G; Bizot MN; Geissler J; Schmidli H
Ther Drug Monit; 2004 Oct; 26(5):499-505. PubMed ID: 15385832
[TBL] [Abstract][Full Text] [Related]
16. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study.
Spagnoletti G; Favi E; Gargiulo A; Salerno MP; Citterio F
Transplant Proc; 2011 May; 43(4):1010-2. PubMed ID: 21620038
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
18. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.
Billaud EM; Antoine C; Berge M; Abboud I; Lefeuvre S; Benammar M; Glotz D
Clin Drug Investig; 2009; 29(7):481-486. PubMed ID: 19499965
[TBL] [Abstract][Full Text] [Related]
19. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Kovarik JM; Kaplan B; Tedesco Silva H; Kahan BD; Dantal J; Vitko S; Boger R; Rordorf C
Transplantation; 2002 Mar; 73(6):920-5. PubMed ID: 11923693
[TBL] [Abstract][Full Text] [Related]
20. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation.
van Gelder T; Fischer L; Shihab F; Shipkova M
Transplant Rev (Orlando); 2017 Jul; 31(3):151-157. PubMed ID: 28279567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
